By Fineline Cube 
JW Therapeutics Ltd. (HKG: 2126) announced today the signing of a supplementary strategic cooperation agreement with Regeneron Pharmaceuticals Inc (NASDAQ: REGN). The deal upgrades a long‑standing partnership and opens a new phase of joint development in TCR‑T cell therapy and platform technology.
Background
- October 2022 – JW Therapeutics partnered with 2seventy bio (now part of Regeneron) to develop solid‑tumor therapies around 2seventy’s MAGE‑A4 T‑cell receptor (TCR) platform.
- The new agreement broadens collaboration beyond the original scope, adding core technology licensing and manufacturing rights.
Key Provisions of the Supplementary Agreement
| Item | Details |
|---|---|
| Global Licensing | Regeneron receives a non‑exclusive worldwide license to JW Therapeutics’ proprietary drug‑product‑process technology. |
| Manufacturing Option | Regeneron obtains the option to acquire JW’s lentiviral vector manufacturing process technology. |
| Funding & Payments | Regeneron will provide upfront capital and a series of milestone payments for JW’s MAGE‑A4 target product. |
| Total Potential Value | Up to USD 50 million in milestone payments, regulatory milestone fees, option‑exercise fees, and lentiviral vector payments. |
Strategic Implications
- Accelerated Development – The funding will fast‑track the MAGE‑A4 product pipeline and streamline regulatory milestones.
- Technology Synergy – Licensing of JW’s process technology and lentiviral manufacturing option positions Regeneron to scale production of next‑generation TCR‑T therapies.
- Market Positioning – The partnership strengthens both companies’ foothold in the rapidly growing cell‑and‑gene‑therapy arena, targeting solid‑tumor indications.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech